the purpose of the study is to assess the safety and efficacy of commonly used Homeopathic medicine Rhustoxicodendron in 30 potency in the treatment of Rheumatoid arthritis.

it is a multicenter phase 2 ,double blind study in patient with active Rheumatoid arthritis ,there are 2 group in the study A and B ,where group A receive Rhustoxicodendron in 30 potency the first dose will administered orally (1/2 ml)after the completion of case taking ,and repeated every 7th day for 5 month and on the other hand group B receive placebo orally in (1/2 ml) at same interval for same period .

Inclusion Criteria:

• those who will provide written consent to participate in the study
• patient willing to turn up for 7th day follow up
• patient who are willing and compliance to the study
• those who are between 25 to 60 years .
• patient who are willing and compliance to the study .
• ESR more then 28 mm.

Exclusion Criteria:

• Participating as a subject in any other clinical research study.
• Children below the age of 25years.
• Female subject who are pregnant or planning for pregnancy within 6 month.
• History of seizures
• Breast feeding women's.
• Patient on treatment for life threatening illness like cancer aids etc.
• Patient should not have any congenital abnormality or patient should not have undergone any operative procedure as consequences of RA.